AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 4061105
Drug: Diltiazem 90
RxNorm normalized name: diltiazem 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 90 mg four times daily
Trial: 4061105
Drug: Propranolol 60
RxNorm normalized name: propranolol 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 60 mg four times daily
Trial: 4061105
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diltiazem and propranolol (90 mg and 60 mg respectively, both four times daily)
Trial: 30505414
Drug: Surgical-site injections
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical-site injections (SIs) with a mixture of epinephrine hydrochloride, morphine sulfate, ropivacaine HCL, and normal saline.
Trial: 30505414
Drug: Surgical-site injections
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical-site injections (SIs)
Trial: 30505414
Drug: No surgical-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No surgical-site injections (no-SI)
Trial: 30505414
Drug: Surgical-site injections
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical-site injections (SIs) and no-SI
Trial: 26693818
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with spironolactone addition
Trial: 24359050
Drug: Intramuscular dexketoprofen
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular dexketoprofen trometamol with paracervical block
Trial: 24359050
Drug: Intramuscular dexketoprofen
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular dexketoprofen trometamol without paracervical block
Trial: 15208157
Drug: Ethanol (0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.45 g/kg b.w.) with placebo
Trial: 15208157
Drug: Ethanol (0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.45 g/kg b.w.) with propranolol (40 mg at 08:00 and 20 mg at 12:00)
Trial: 9602954
Drug: Terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (250 mg daily for 3 days)
Trial: 15025403
Drug: TNX-901 (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNX-901 (450 mg)
Trial: 15025403
Drug: TNX-901 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNX-901 (150 mg)
Trial: 15025403
Drug: TNX-901 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNX-901 (300 mg)
Trial: 11242179
Drug: Cotrimoxazole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (80 mg of trimethoprim and 400 mg of sulphamethoxazole daily)
Trial: 12196422
Drug: Troglitazone 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 600 mg
Trial: 9745421
Drug: Troglitazone 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 600 mg (diet-only subset)
Trial: 9745421
Drug: Troglitazone 200
RxNorm normalized name: troglitazone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 200 mg (sulfonylurea subset)
Trial: 9745421
Drug: Troglitazone 400
RxNorm normalized name: troglitazone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 400 mg (sulfonylurea subset)
Trial: 9745421
Drug: Troglitazone 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 600 mg (sulfonylurea subset)
Trial: 9745421
Drug: Troglitazone 400
RxNorm normalized name: troglitazone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone 400 mg and 600 mg
Trial: 2109465
Drug: Flumazenil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (0.5 mg i.v.)
Trial: 31669449
Drug: Hybrid designs
RxNorm normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hybrid designs in vaccine development
Trial: 28385433
Drug: Simplified edentulous
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simplified edentulous treatment (SET)
Trial: 25609193
Drug: Trelagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trelagliptin (100 mg once per week)
Trial: 25609193
Drug: Alogliptin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin (25 mg once per day)
Trial: 21366599
Drug: Intranasal phototherapy
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal phototherapy (three times a week for 2 weeks)
Trial: 21366599
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl (180 mg per day for 2 weeks)
Trial: 19711095
Drug: Combined nebulized
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined nebulized bronchodilators (BD)
Trial: 14644068
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of dexamethasone (DEX)
Trial: 11443153
Drug: GH (genotropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (genotropin 4 IU/m(2).day) and GnRHa (triptorelin, 3.75 mg/28 days)
Trial: 8148931
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg dexfenfluramine (DF) twice daily
Trial: 8148931
Drug: 20 mg/200
RxNorm normalized name: niCARdipine 20 mg/200 mL-D4.8% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/200 mg ephedrine/caffeine (EC) three times a day
Trial: 23402525
Drug: Minimal Psychological
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal Psychological Intervention (MPI) administered by trained nurses in cognitive behavioural therapy and self-management.
Trial: 18784526
Drug: 0.5% sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% sterile solution of metronidazole (2 mL, 10 mg) incorporated in the sinus bone graft
Trial: 16898076
Drug: New retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New retard tablet formulation (240mg oral)
Trial: 16898076
Drug: Standard retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard retard tablet formulation (240mg oral)
Trial: 16898076
Drug: Intravenous dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose (5mg)
Trial: 14597782
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (3 mg in 10 ml saline)
Trial: 11070572
Drug: Mebeverine hydrochloride
RxNorm normalized name: Mebeverine hydrochloride
DrugBank: Mebeverine (DB12554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine hydrochloride 135 mg t.i.d. (Colofac)
Trial: 11070572
Drug: Mebeverine hydrochloride
RxNorm normalized name: Mebeverine hydrochloride
DrugBank: Mebeverine (DB12554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine hydrochloride 200 mg b.i.d. (Colofac MR)
Trial: 1450803
Drug: Intralesional corticosteroid
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional corticosteroid injection (methylprednisolone and lignocaine)
Trial: 1450803
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (lignocaine alone)
Trial: 6363095
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of MA
Trial: 6363095
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg of MA
Trial: 6363095
Drug: 270 mg
RxNorm normalized name: leucine 270 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 270 mg of MA
Trial: 26884559
Drug: Doxorubicin, bleomycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by ifosfamide-containing salvage treatment and stem-cell transplantation for PET2-positive patients
Trial: 20871804
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy in home care (PST-HC)
Trial: 17617743
Drug: DTwP-HepB-Hib vaccine
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP-HepB-Hib vaccine administered at 0, 4, and 8 weeks
Trial: 17617743
Drug: DTwP-HepB-Hib vaccine
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP-HepB-Hib vaccine
Trial: 8654899
Drug: Ineraid cochlear
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ineraid cochlear implant users
Trial: 387001
Drug: Luteinizing hormone-releasing
RxNorm normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone-releasing hormone (LRH, 500 micrograms, intramuscularly injected)
Trial: 30986809
Drug: CDK4/6 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitors (palbociclib or ribociclib) in combination with cetuximab
Trial: 30986809
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of palbociclib/cetuximab
Trial: 30986809
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies (CDK4/6 inhibitors with other agents)
Trial: 23792937
Drug: Cholecalciferol and
RxNorm normalized name: Cholecalciferol and retinol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol and Ergocalciferol (both treatments)
Trial: 21035237
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg submucosally
Trial: 21035237
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg intramuscularly
Trial: 15135483
Drug: G17DT antibodies
RxNorm normalized name: G17DT
DrugBank: G17DT Immunogen (DB04914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G17DT antibodies
Trial: 11466984
Drug: Presumed non-effective
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presumed non-effective reflexological treatment (Group A)
Trial: 11466984
Drug: Presumed effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presumed effective reflexological treatment (Group B)
Trial: 11466984
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment - only observation (Group C)
Trial: 9728931
Drug: LPONL(G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPONL(G)
Trial: 4448876
Drug: Modeling treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modeling treatment
Trial: 25887238
Drug: Multifaceted educational
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted educational program for nursing home care staff on assessment and treatment of fecal incontinence
Trial: 23190342
Drug: IncobotulinumtoxinA (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IncobotulinumtoxinA (20 U per cycle, up to eight treatment cycles, treatment interval at least 85 days)
Trial: 22191131
Drug: Vacuum Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum Assisted Closure (VAC) therapy
Trial: 19656069
Drug: Mefloquine (MQ)
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefloquine (MQ) 15 mg/kg in a single intake twice during pregnancy
Trial: 19656069
Drug: Sulfadoxine-pyrimethamine (SP)
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine (SP) 1500 mg sulfadoxine and 75 mg pyrimethamine in a single intake twice during pregnancy
Trial: 16291984
Drug: Sildenafil 20
RxNorm normalized name: sildenafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 20 mg
Trial: 30383134
Drug: Sildenafil 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 40 mg
Trial: 30383134
Drug: Sildenafil 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 80 mg
Trial: 12920042
Drug: Desmopressin (DDAVP)
RxNorm normalized name: desmopressin Injection [DDAVP]
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin (DDAVP) infusion
Trial: 12920042
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline infusion (placebo)
Trial: 10839552
Drug: Antibiotics (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (dosage and duration not specified)
Trial: 10839552
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs, alpha-blocking agents, anticholinergic agents or other therapies
Trial: 3533264
Drug: Captopril 150
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril 150 mg daily
Trial: 3533264
Drug: Methyldopa 750
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa 750 mg daily
Trial: 25038985
Drug: High-frequency deep
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency deep TMS treatment
Trial: 25038985
Drug: Low-frequency deep
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency deep TMS treatment
Trial: 22858177
Drug: Revaprazan 200
RxNorm normalized name: Revaprazan
DrugBank: Revaprazan (DB16308)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revaprazan 200 mg once daily for 7 days
Trial: 22858177
Drug: Itopride 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itopride 50 mg TID for 7 days
Trial: 22858177
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of revaprazan and itopride
Trial: 20133068
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (500 μg of sodium selenite during RT and 300 μg on non-RT days)
Trial: 10368794
Drug: Oral DHEAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral DHEAS (50 mg/day)
Trial: 10368794
Drug: Oral DHEAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral DHEAS (50 mg/day) + transdermal estradiol (50 micrograms/patch)
Trial: 1877335
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control) for 31/2 weeks
Trial: 7174915
Drug: Topical 8‐methoxypsoralen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 8‐methoxypsoralen (8‐MOP) 0.1%
Trial: 7174915
Drug: Topical 8‐methoxypsoralen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 8‐methoxypsoralen (8‐MOP) 0.5%
Trial: 7174915
Drug: Topical 8‐methoxypsoralen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 8‐methoxypsoralen (8‐MOP) 1%
Trial: 7174915
Drug: Topical 8‐methoxypsoralen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 8‐methoxypsoralen (8‐MOP)
Trial: 25431880
Drug: Control (alternative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (alternative meal, e.g., chicken, pork, or beef three times per week during the same period)
Trial: 22260297
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine 1.5 mg/kg followed by a continuous infusion of 2 mg/kg/h
Trial: 17352868
Drug: Chaige Qingre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chaige Qingre Granule (6 g, 4 times daily for 3 days)
Trial: 17352868
Drug: Fufang Shuanghua
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang Shuanghua Granule (6 g, 4 times daily for 3 days)
Trial: 12885350
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with 10(7) or 10(8) irradiated CD80-modified tumor cells with GM-CSF or BCG, three times at 2-week intervals and then monthly until progressive disease developed.
Trial: 12885350
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with 10(8) tumor cell dose.
Trial: 9346678
Drug: ganciclovir (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ganciclovir (6 mg/kg/day intravenously for a total of 100 days)
Trial: 9346678
Drug: acyclovir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: acyclovir (10 mg/kg every 8 hours intravenously until discharged and then 800 mg orally every 6 hours for a total of 100 days)
Trial: 30382352
Drug: Remotiv 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remotiv 250 (250 mg of H. perforatum)
Trial: 30382352
Drug: Remotiv 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remotiv 500 (500 mg of H. perforatum)
Trial: 26358764
Drug: Topical combination
RxNorm normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical combination of calcipotriol and betamethasone (Group A)
Trial: 18574489
Drug: Regular passive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular passive movements administered for 10 min, 10 times a week for 6 months.
Trial: 8633581
Drug: Chloroquine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (500 mg/day)
Trial: 29326330
Drug: Multi-component intervention
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component intervention including individualised care/action plans and telephone consults (12-weekly then 9-monthly)
Trial: 27279511
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block using 20 mL 0.25% bupivacaine
Trial: 27279511
Drug: Control block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control block using 20 mL 0.9% Sodium chloride
Trial: 19578163
Drug: Pravastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin therapy (40 mg/day)
Trial: 16173357
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy
Trial: 16173357
Drug: Trauma Model
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma Model Therapy
Trial: 9885787
Drug: CCK-4 injection
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK-4 injection during the follicular phase
Trial: 9885787
Drug: CCK-4 injection
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK-4 injection during the luteal phase
Trial: 9885787
Drug: CCK-4 injection
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK-4 injection (both phases)
Trial: 7726308
Drug: Lactate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate infusion with 0.9% sodium chloride
Trial: 7726308
Drug: Lactate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate infusion with 5% dextrose in water
Trial: 7726308
Drug: Both infusions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both infusions
Trial: 2174121
Drug: MK-571 (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-571 (160 mg)
Trial: 30992301
Drug: Ixazomib in
RxNorm normalized name: Product containing ixazomib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixazomib in combination with MEC (mitoxantrone, etoposide, cytarabine)
Trial: 28033159
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mL of 0.4% dexamethasone)
Trial: 28033159
Drug: Control (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (1 mL of saline)
Trial: 25450293
Drug: Leptin treatment
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin treatment in cultured endometrial cells (Ishikawa cells)
Trial: 19923847
Drug: Extended-interval dosing
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-interval dosing (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses)
Trial: 19923847
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing (1 injection every 4 weeks for a total of 6 doses)
Trial: 17427818
Drug: Self-etching, self-priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching, self-priming dentin bonding agent
Trial: 9475525
Drug: No photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No photodynamic therapy
Trial: 7620004
Drug: Piperacillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (4 g) three times daily for up to 7 days
Trial: 7620004
Drug: Placebo three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times daily for up to 7 days
Trial: 2244441
Drug: Bupivacaine-epinephrine mixture
RxNorm normalized name: bupivacaine / epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-epinephrine mixture (0.5% bupivacaine, 5 micrograms/ml epinephrine)
Trial: 31332549
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation plus routine antihistamine medication (cetirizine)